Halozyme Therapeutics, Inc. (Form: 8-K)  






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   October 28, 2004

Halozyme Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Nevada   000-49616   88-0488686
(State or other jurisdiction
(I.R.S. Employer
of incorporation)   File Number)   Identification No.)
11588 Sorrento Valley Road, Suite 17, San Diego, California       92121
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   (858) 794-8889

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01. Other Events.

On October 22, 2004, Halozyme Therapeutics, Inc. (the "Company") received notice from the American Stock Exchange ("AMEX") that it had approved the Company’s application to transfer the listing of the Company’s securities from the OTC Bulletin Board. The Company’s securities are expected to commence trading on AMEX at the opening of business on November 1, 2004. The stock trading symbol for the Company will change to "HTI." Please see the attached Press Release dated October 25, 2004.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit -- Description
99.1 -- Press Release issued by the Company on October 25, 2004

Top of the Form


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Halozyme Therapeutics, Inc.
October 28, 2004   By:   Jonathan E. Lim, M.D.
        Name: Jonathan E. Lim, M.D.
        Title: President and Chief Executive Officer

Top of the Form

Exhibit Index

Exhibit No.   Description

  Press Release issued by the Company on October 25, 2004